Wednesday , November 22 2017
Home / Endocrinology

Endocrinology

NYU Stern Study Shows Significant Health Improvement in Diabetes Patients with Mobile Health Applications

NEW YORK–(BUSINESS WIRE)–New research “Empowering Patients Using Smart Mobile Health Platforms: Evidence from a Randomized Field Experiment,” from NYU Stern Professor Anindya Ghose and co-authors, Beibei Li of Carnegie Mellon University and Xitong Guo of the Harbin Institute of Technology, explores how emerging mobile health (mHealth) technologies can persuade chronic-disease patients to …

Read More »

FDA Approves New Once-Weekly Bydureon BCise Injectable Medicine for Type 2 Diabetes

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON® (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines …

Read More »

Merck’s Follow-On Biologic Basal Insulin Granted Tentative Approval from the FDA

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for LUSDUNA™ Nexvue™ (insulin glargine injection) 100 units/mL, a follow-on biologic1 basal insulin in a pre-filled dosing device. LUSDUNA Nexvue is being developed …

Read More »

CDC Report Finds More than 100 Million Americans have Diabetes or Prediabetes

ATLANTA, July 18, 2017 /PRNewswire-USNewswire/ — More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released today by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans – 9.4 percent of the …

Read More »

Johnson & Johnson Innovation Announces New Collaborations Advancing Ground-Breaking Biomedical Innovation

NEW BRUNSWICK, N.J., June 15, 2017 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced new collaborations that seek to develop potential treatments for diseases in urgent need of solutions, including obesity and related complications, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), and rheumatoid arthritis, and advance cutting-edge …

Read More »

Merck and Pfizer Announce Investigational SGLT-2 Inhibitor Met Primary Endpoint in Two Phase 3 Studies

KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults …

Read More »

Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …

Read More »

Rates of New Diagnosed Cases of Type 1 and 2 Diabetes on the Rise Among Children, Teens

Rates of new diagnosed cases of type 1 and type 2 diabetes are increasing among youth in the United States, according to a report, Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012, published today in the New England Journal of Medicine. In the United States, 29.1 …

Read More »

Two Prime Therapeutics Studies Examine Diabetes Costs, How Appropriate Preventive Care Can Improve Outcomes

ST. PAUL, Minn.–(BUSINESS WIRE)–Two new studies find commercially insured members with diabetes had 2.5 times higher medical and pharmacy spending than members without diabetes matched by age, sex, state of residence and insurer. But those taking a cholesterol-lowering statin for primary prevention of heart disease – a common complication of …

Read More »

Enteris BioPharma and Sanofi Enter Deal to Develop Oral Diabetes Drug

BOONTON, N.J., Jan. 23, 2017 /PRNewswire/ — Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides. Joel Tune, Chief …

Read More »